287 related articles for article (PubMed ID: 17928597)
1. HER2 and response to paclitaxel in node-positive breast cancer.
Hayes DF; Thor AD; Dressler LG; Weaver D; Edgerton S; Cowan D; Broadwater G; Goldstein LJ; Martino S; Ingle JN; Henderson IC; Norton L; Winer EP; Hudis CA; Ellis MJ; Berry DA;
N Engl J Med; 2007 Oct; 357(15):1496-506. PubMed ID: 17928597
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
Pusztai L; Jeong JH; Gong Y; Ross JS; Kim C; Paik S; Rouzier R; Andre F; Hortobagyi GN; Wolmark N; Symmans WF
J Clin Oncol; 2009 Sep; 27(26):4287-92. PubMed ID: 19667268
[TBL] [Abstract][Full Text] [Related]
4. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC
Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055
[TBL] [Abstract][Full Text] [Related]
5. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.
Sparano JA; Goldstein LJ; Childs BH; Shak S; Brassard D; Badve S; Baehner FL; Bugarini R; Rowley S; Perez EA; Shulman LN; Martino S; Davidson NE; Kenny PA; Sledge GW; Gray R
Clin Cancer Res; 2011 Nov; 17(22):7194-203. PubMed ID: 21933890
[TBL] [Abstract][Full Text] [Related]
6. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Werida RH; Elshafiey RA; Ghoneim A; Elzawawy S; Mostafa TM
Support Care Cancer; 2022 Sep; 30(9):7281-7292. PubMed ID: 35596774
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.
Ito Y; Nagasaki K; Miki Y; Iwase T; Akiyama F; Matsuura M; Horii R; Makita M; Tokudome N; Ushijima M; Yoshimoto M; Takahashi S; Noda T; Hatake K
Cancer Sci; 2011 Jan; 102(1):130-6. PubMed ID: 20880335
[TBL] [Abstract][Full Text] [Related]
8. Immunological effects of taxol and adryamicin in breast cancer patients.
Panis C; Lemos LG; Victorino VJ; Herrera AC; Campos FC; Colado Simão AN; Pinge-Filho P; Cecchini AL; Cecchini R
Cancer Immunol Immunother; 2012 Apr; 61(4):481-8. PubMed ID: 21959683
[TBL] [Abstract][Full Text] [Related]
9. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients.
Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
[TBL] [Abstract][Full Text] [Related]
10. De-escalation of adjuvant chemotherapy for HER2 negative breast cancer.
Okines DAF; Parton DM
Lancet Reg Health West Pac; 2021 Jun; 11():100177. PubMed ID: 34327370
[No Abstract] [Full Text] [Related]
11. Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
Radford J
J Clin Oncol; 2024 Jun; 42(16):1868-1870. PubMed ID: 38478798
[No Abstract] [Full Text] [Related]
12. Weekly paclitaxel in the adjuvant treatment of breast cancer.
Sparano JA; Wang M; Martino S; Jones V; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
N Engl J Med; 2008 Apr; 358(16):1663-71. PubMed ID: 18420499
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D; Eiermann W; Robert N; Pienkowski T; Martin M; Press M; Mackey J; Glaspy J; Chan A; Pawlicki M; Pinter T; Valero V; Liu MC; Sauter G; von Minckwitz G; Visco F; Bee V; Buyse M; Bendahmane B; Tabah-Fisch I; Lindsay MA; Riva A; Crown J;
N Engl J Med; 2011 Oct; 365(14):1273-83. PubMed ID: 21991949
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
15. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
Goldhirsch A; Winer EP; Coates AS; Gelber RD; Piccart-Gebhart M; Thürlimann B; Senn HJ;
Ann Oncol; 2013 Sep; 24(9):2206-23. PubMed ID: 23917950
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Version 2.2015.
Gradishar WJ; Anderson BO; Balassanian R; Blair SL; Burstein HJ; Cyr A; Elias AD; Farrar WB; Forero A; Giordano SH; Goetz M; Goldstein LJ; Hudis CA; Isakoff SJ; Marcom PK; Mayer IA; McCormick B; Moran M; Patel SA; Pierce LJ; Reed EC; Salerno KE; Schwartzberg LS; Smith KL; Smith ML; Soliman H; Somlo G; Telli M; Ward JH; Shead DA; Kumar R
J Natl Compr Canc Netw; 2015 Apr; 13(4):448-75. PubMed ID: 25870381
[TBL] [Abstract][Full Text] [Related]
17. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
Lara JF; Thor AD; Dressler LG; Broadwater G; Bleiweiss IJ; Edgerton S; Cowan D; Goldstein LJ; Martino S; Ingle JN; Henderson IC; Norton L; Winer EP; Hudis CA; Ellis MJ; Berry DA; Hayes DF;
Clin Cancer Res; 2011 Aug; 17(15):5170-8. PubMed ID: 21693655
[TBL] [Abstract][Full Text] [Related]
18. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E; ;
Breast; 2014 Oct; 23(5):489-502. PubMed ID: 25244983
[No Abstract] [Full Text] [Related]
19. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E
Ann Oncol; 2014 Oct; 25(10):1871-1888. PubMed ID: 25234545
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
